share_log

Apollomics | EFFECT: Others

Apollomics | EFFECT: Others

Apollomics | EFFECT:其他
美股sec公告 ·  04/25 06:05
Moomoo AI 已提取核心信息
The United States Securities and Exchange Commission (SEC) has declared a Form F-3 filing by Apollomics Inc. effective as of April 24, 2024, at 5:00 PM. This notice of effectiveness allows Apollomics, a biopharmaceutical company, to potentially offer and sell securities in the future. The Form F-3, associated with file number 333-278430, is a registration statement used by foreign private issuers to register securities offerings in the U.S. market. The effectiveness of this filing is a regulatory step that enables Apollomics to access U.S. capital markets for potential fundraising activities.
The United States Securities and Exchange Commission (SEC) has declared a Form F-3 filing by Apollomics Inc. effective as of April 24, 2024, at 5:00 PM. This notice of effectiveness allows Apollomics, a biopharmaceutical company, to potentially offer and sell securities in the future. The Form F-3, associated with file number 333-278430, is a registration statement used by foreign private issuers to register securities offerings in the U.S. market. The effectiveness of this filing is a regulatory step that enables Apollomics to access U.S. capital markets for potential fundraising activities.
美国证券交易委员会(SEC)已宣布Apollomics Inc.提交的F-3表格自2024年4月24日下午5点起生效。该生效通知使生物制药公司Apollomics有可能在未来发行和出售证券。文件编号为333-278430的F-3表格是外国私人发行人用来在美国市场注册证券发行的注册声明。该申请的有效性是一项监管措施,使Apollomics能够进入美国资本市场进行潜在的筹款活动。
美国证券交易委员会(SEC)已宣布Apollomics Inc.提交的F-3表格自2024年4月24日下午5点起生效。该生效通知使生物制药公司Apollomics有可能在未来发行和出售证券。文件编号为333-278430的F-3表格是外国私人发行人用来在美国市场注册证券发行的注册声明。该申请的有效性是一项监管措施,使Apollomics能够进入美国资本市场进行潜在的筹款活动。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息